Find your next paid study

National Cancer Institute (NCI)NCT01313442

~$10 – $675

Actual pay is set by the research site.

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Re…

Very Rare TumorsVery Rare CancersOther Solid Tumors+2 more

National Cancer Institute (NCI)NCT07489378

~$10 – $675

Actual pay is set by the research site.

Brain (Nervous System) Cancers

A Window-of-Opportunity Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High-Grade Glioma

This research study is for participants with glioblastoma. It can cause a tumor immunosuppression which helps myeloid cells that can stop T-cell function. Disu…

Case Comprehensive Cancer CenterNCT07719127

~$150 – $3,000

Actual pay is set by the research site.

Endometrial Cancer RecurrentEndometrial CancerAdvanced Endometrial Cancer+4 more

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the…

Outpace Bio, Inc.NCT07664735

~$150 – $4,200

Actual pay is set by the research site.

Phase 4

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development,…

MelanomaNon Small Cell Lung CancerSolid Tumor+2 more

Novartis PharmaceuticalsNCT03340506

~$25 – $1,400

Actual pay is set by the research site.

Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau Disease+2 more

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic n…

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLC

Gastric CancerGastric AdenocarcinomaGastric (Stomach) Cancer+11 more

Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how…

~$150 – $4,200

Actual pay is set by the research site.

Metastatic CancersFatigue

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to imp…

M.D. Anderson Cancer CenterNCT06085716

~$75 – $2,000

Actual pay is set by the research site.

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-in…

~$75 – $2,800

Actual pay is set by the research site.

MeiraGTx, LLCNCT06544798

Hepatopancreaticobiliary (HPB) MalignancyOvarian Cancer (OvCa)Kidney Cancers+1 more

Comprehensive Multimodal Prehabilitation Alone or in Combination With Planned Neoadjuvant Therapy in High-risk Patients Prior to Elective Major Cancer Surgery

In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone…

The Methodist Hospital Research InstituteNCT07050771

~$75 – $2,000

Actual pay is set by the research site.

Genomic Analysis of Families With a History of Discordant Cancers

The purpose of this study is to identify novel gene mutations which have contributed to significant personal and family history of cancer. Adults with and with…

Discordant Cancers

Case Comprehensive Cancer CenterNCT04860453

~$10 – $750

Actual pay is set by the research site.

Colorectal CancerPancreatic CancerMelanoma+13 more

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid …